195 related articles for article (PubMed ID: 16005383)
21. A family study of schizophrenic and normal control probands: implications for the spectrum concept of schizophrenia.
Baron M; Gruen R; Rainer JD; Kane J; Asnis L; Lord S
Am J Psychiatry; 1985 Apr; 142(4):447-55. PubMed ID: 3976917
[TBL] [Abstract][Full Text] [Related]
22. Validating schizotaxia and its place in studies of preventing schizophrenia by psychopharmacological intervention.
Tsuang MT; Stone WS; Tarbox SI; Faraone SV
Essent Psychopharmacol; 2005; 6(2):91-103. PubMed ID: 15765793
[TBL] [Abstract][Full Text] [Related]
23. Orienting of attention in unmedicated patients with schizophrenia, prodromal subjects and healthy relatives.
Gouzoulis-Mayfrank E; Balke M; Hajsamou S; Ruhrmann S; Schultze-Lutter F; Daumann J; Heekeren K
Schizophr Res; 2007 Dec; 97(1-3):35-42. PubMed ID: 17869065
[TBL] [Abstract][Full Text] [Related]
24. Examining the validity of DSM-III-R schizoaffective disorder and its putative subtypes in the Roscommon Family Study.
Kendler KS; McGuire M; Gruenberg AM; Walsh D
Am J Psychiatry; 1995 May; 152(5):755-64. PubMed ID: 7726316
[TBL] [Abstract][Full Text] [Related]
25. Familial schizophrenia and treatment response.
Silverman JM; Mohs RC; Davidson M; Losonczy MF; Keefe RS; Breitner JC; Sorokin JE; Davis KL
Am J Psychiatry; 1987 Oct; 144(10):1271-6. PubMed ID: 3661762
[TBL] [Abstract][Full Text] [Related]
26. Psychometric evaluation of the Subjective Well-being Under Neuroleptic Treatment Scale (SWN) in patients with schizophrenia, their relatives and controls.
Vothknecht S; Meijer C; Zwinderman A; Kikkert M; Dekker J; van Beveren N; Schoevers R; de Haan L;
Psychiatry Res; 2013 Mar; 206(1):62-7. PubMed ID: 23021423
[TBL] [Abstract][Full Text] [Related]
27. Psychiatric illnesses in families of subjects with schizophrenia-spectrum personality disorders: high morbidity risks for unspecified functional psychoses and schizophrenia.
Thaker G; Adami H; Moran M; Lahti A; Cassady S
Am J Psychiatry; 1993 Jan; 150(1):66-71. PubMed ID: 8417582
[TBL] [Abstract][Full Text] [Related]
28. Heterogeneity of schizophrenia: relationship to latency of neuroleptic response.
McDermott BE; Sautter FJ; Garver DL
Psychiatry Res; 1991 Apr; 37(1):97-103. PubMed ID: 1862165
[TBL] [Abstract][Full Text] [Related]
29. Familial differences between rapid neuroleptic response psychosis and delayed neuroleptic response psychosis.
Sautter F; McDermott B; Garver D
Biol Psychiatry; 1993 Jan; 33(1):15-21. PubMed ID: 8093593
[TBL] [Abstract][Full Text] [Related]
30. Modern research criteria and the genetics of schizophrenia.
Baron M; Gruen R; Kane J; Asnis L
Am J Psychiatry; 1985 Jun; 142(6):697-701. PubMed ID: 4003588
[TBL] [Abstract][Full Text] [Related]
31. Age at onset, sex, and familial psychiatric morbidity in schizophrenia. Camberwell Collaborative Psychosis Study.
Sham PC; Jones P; Russell A; Gilvarry K; Bebbington P; Lewis S; Toone B; Murray R
Br J Psychiatry; 1994 Oct; 165(4):466-73. PubMed ID: 7804660
[TBL] [Abstract][Full Text] [Related]
32. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia.
Gur RE; Maany V; Mozley PD; Swanson C; Bilker W; Gur RC
Am J Psychiatry; 1998 Dec; 155(12):1711-7. PubMed ID: 9842780
[TBL] [Abstract][Full Text] [Related]
33. A follow-up MRI study of the superior temporal subregions in schizotypal disorder and first-episode schizophrenia.
Takahashi T; Suzuki M; Zhou SY; Tanino R; Nakamura K; Kawasaki Y; Seto H; Kurachi M
Schizophr Res; 2010 Jun; 119(1-3):65-74. PubMed ID: 20051316
[TBL] [Abstract][Full Text] [Related]
34. Identification of vulnerability among first-degree relatives of patients with schizophrenia.
Solanki RK; Swami MK; Singh P; Gupta S
East Asian Arch Psychiatry; 2012 Sep; 22(3):118-25. PubMed ID: 23019286
[TBL] [Abstract][Full Text] [Related]
35. Testing the effect of season of birth on familial risk for schizophrenia and related disorders.
Hettema JM; Walsh D; Kendler KS
Br J Psychiatry; 1996 Feb; 168(2):205-9. PubMed ID: 8837911
[TBL] [Abstract][Full Text] [Related]
36. [Cognitive deficits in first episode psychosis patients and people at risk for psychosis: from diagnosis to treatment].
Lecardeur L; Meunier-Cussac S; Dollfus S
Encephale; 2013 May; 39 Suppl 1():S64-71. PubMed ID: 23528322
[TBL] [Abstract][Full Text] [Related]
37. The predictive value of psychopathological subclassifications for the neuroleptic treatment outcome in schizophrenia.
Jarema M; Kacperczyk J; Kruszynski S
Psychopathology; 1991; 24(3):141-6. PubMed ID: 1684443
[TBL] [Abstract][Full Text] [Related]
38. Neuropsychological impairments in neuroleptic-responder vs. -nonresponder schizophrenic patients and healthy volunteers.
Joober R; Rouleau GA; Lal S; Dixon M; O'Driscoll G; Palmour R; Annable L; Bloom D; Lalonde P; Labelle A; Benkelfat C
Schizophr Res; 2002 Jan; 53(3):229-38. PubMed ID: 11738536
[TBL] [Abstract][Full Text] [Related]
39. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
[TBL] [Abstract][Full Text] [Related]
40. [Profile of the action of neuroleptics in deficit schizophrenia].
Vanelle JM
Encephale; 1996 Jun; 22 Spec No 2():33-9. PubMed ID: 8767040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
